Why is Revolution Medicines shipping daraxonrasib before FDA approval?

Revolution Medicines has started shipping its experimental pancreatic cancer drug, daraxonrasib, even before filing for FDA approval. The company’s early move reflects strong confidence in the drug’s performance and close coordination between manufacturing and regulatory teams, signaling readiness for commercial and expanded-access phases.